TRACON Pharmaceuticals Stock News

Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug candidate Envafolimab could provide certain advantage

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab a

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference C

TRACON Pharmaceuticals Inc announced that it has ended its third-quarter 2022 with cash and equivalents of $17.0 million as of September 30, 2022, which the company says is expected to fund its oper

TRACON Pharmaceuticals Inc has received a recommendation from the Independent Data Monitoring Committee that its ENVASARC Phase 2 pivotal trial can proceed as planned, the company announced. The comm

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced that its undifferentiated pleomorphic sarcoma (UPS) drug envafolimab has been granted fast track designation by the US Food and Drug Administration.

TRACON Pharmaceuticals Inc (NASDAQ:TCON) has announced a $35 million non-dilutive long-term debt facility with Runway Growth Capital LLC to support its ongoing pivotal ENVASARC trial to treat cancer a

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said the US Food and Drug Administration (FDA) has approved its Investigational New Drug application for the initiation of a phase one-two clinical trial of Y

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Charles Theuer - President and Chief Executive Officer Scott Brown - Chief

TRACON Pharmaceuticals (NASDAQ:TCON) Inc rounded out the second quarter with a strong cash runway to carry out key trials and continue hitting significant milestones. The San Diego, Califoria-based

TRACON Pharmaceuticals (NASDAQ:TCON) Inc announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial proceed as planned. The update follows a

TRACON Pharmaceuticals (NASDAQ:TCON) Inc announced that it has submitted an application to initiate a trial combining a new drug to be taken in combination with two other medications by patients with

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform

TRACON Pharmaceuticals (NASDAQ:TCON) Inc said an initial independent data monitoring committee (IDMC) interim efficacy analysis of its ENVASARC pivotal trial is set to take place in 4Q following the e